On July 24, 2026, a federal district court in Virginia ruled that the Food and Drug Administration’s (FDA) restrictions on the abortion pill mifepristone are “baseless” and “unjustified” because the agency disregarded extensive scientific evidence. Research has demonstrated that the medication can be safely prescribed without burdensome regulations. Nancy Northup, President and CEO of the Center for Reproductive Rights, said the FDA’s restrictions “were never about science or safety,” but rather “about making abortion harder to access.”
The court ordered the FDA to reconsider its restrictions, noting that the agency has repeatedly concluded that mifepristone is “safe and effective.” The ruling aligns with decades of scientific research confirming the medication’s safety. When used as directed, mifepristone has a 95–99% effectiveness rate and is widely regarded as one of the most accessible, flexible, and cost-effective methods of abortion care. According to reporting, the FDA’s renewed review of the drug was prompted by pressure from anti-abortion lawmakers, activists, and the Trump administration, not by new evidence questioning its safety or efficacy.
The challenged restrictions require healthcare providers and pharmacies to obtain special certification before prescribing or dispensing mifepristone. They also impose additional administrative requirements on patients, forcing them to complete unnecessary paperwork before accessing care they have already chosen to receive.
The decision carries particular significance for Virginia, the last state in the South without a post-Dobbs abortion ban. Reinstating unnecessary restrictions on mifepristone would further limit access not only for Virginians but also for patients traveling from neighboring states where abortion is heavily restricted or banned. Medication abortion now accounts for nearly 60% of all abortions in the United States, making access to mifepristone more critical than ever. As attacks on reproductive freedom continue in the years following Dobbs, abortion policy should be guided by medical evidence—not political pressure. Restricting access to a medication that has repeatedly been proven safe and effective threatens the health, autonomy, and well-being of patients across the country.
